Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXP154B for Minor Wound Bleeding in Patients on Apixaban
NCT06205615Phase 2Completed
- Sponsor
- Bio 54
- Start
- Jan 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BXP-154 in hemorrhage (4 arms), sponsored by Bio 54. Primary endpoint: Time to achieve hemostasis following start of treatment at 60 minutes. Started Jan 2024; status: completed.
02
Drugs
BXP-154
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT06205615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205615.